Story
Science
- Critical Limb Ischemia
- Vascular Dementia
Savings
Events
FAQ
Registry
GLOBAL

Story
Science
- Critical Limb Ischemia
- Vascular Dementia
Savings
Events
FAQ
Registry
GLOBAL

Care Team Navigator

Topic

Wound Care

All Post
Chronic Limb Threatening Ischemia
Heart Failure
Wound Care

Topics

Chronic Limb Threatening Ischemia
Heart Failure
Wound Care

Popular Post

New Hope for Heart Health
Revolutionizing CLI Treatment: Insights from VesCell HealthTalks #10

Subscribe

Revolutionizing CLI Treatment: Insights from VesCell HealthTalks #10

Chronic Limb Threatening Ischemia Wound Care

Revolutionizing CLI Treatment: Insights from VesCell HealthTalks #10

On September 11, 2025, Hemostemix hosted its 10th VesCell HealthTalks webinar, led by Chief...

7 minute read

Croom Lawrence

11 September 2025

Read More

VesCell (ACP-01) is an investigational therapy under development and not approved by the FDA. VesCell is available through special access programs that may be approved on a case-by-case basis in Canada, Bahamas and Domican Republic for treatment of no option patients suffering from CLTI, no option patients suffering from chronic stable angina, no option ischemic and non-ischemic dilated cardiomyopathy.

Resources

Story
Science
- Critical Limb Ischemia
- Vascular Dementia
Savings
Events
FAQ
Registry
GLOBAL

We're here to help

1-239-522-2906

Customer Success: clawrence@hemostemix.com

Corporate Office: tsmeenk@hemostemix.com

707 7 Ave SW #1150 Calgary, AB T2P 3H6

© 2025 Hemostemix Inc. All Rights reserved.

Privacy Policy | Terms & Condition